Roanna Ruiz

Stock Analyst at Leerink Partners

(0)
# 4642
Out of 5,370 analysts
77
Total ratings
38.46%
Success rate
-14.09%
Average return
21 Stocks
Name Action PT Current % Upside Ratings Updated
AKBA Akebia Therapeutics
Initiates Coverage On: Outperform
7
3.56 96.63% 1 Apr 28, 2025
XERS Xeris Biopharma Hold...
Maintains: Outperform
5 6
4.41 36.05% 5 Mar 7, 2025
CRMD Cormedix
Initiates Coverage On: Outperform
18
14.37 25.26% 1 Mar 7, 2025
LXRX Lexicon Pharmaceutic...
Downgrades: Market Perform
1
0.66 51.52% 1 Mar 4, 2025
VIR Vir Biotechnology
Maintains: Outperform
18 20
5.24 281.68% 4 Jan 13, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
26 27
15.13 78.45% 4 Jan 13, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
12 13
3.54 267.23% 3 Oct 25, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
14
3.67 281.47% 1 Apr 5, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
330
288.31 14.46% 1 Feb 5, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
58
33.75 71.85% 1 Aug 15, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Market Perform
25
70.84 -64.71% 1 Apr 11, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
9 2
n/a n/a 4 Apr 4, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Market Perform
49
7.26 574.93% 10 Feb 9, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
12 13
3.98 226.63% 7 Jan 27, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Market Perform
8 6
3.19 88.09% 6 Jan 27, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
19
19.75 -3.8% 1 Dec 20, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
110 120
77.64 54.56% 3 Nov 15, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Market Perform
75 50
8.1 517.28% 7 Nov 3, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
23 27
n/a n/a 7 Oct 25, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Market Perform
60 40
13.82 189.44% 6 Oct 19, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
720 80
n/a n/a 3 Jul 14, 2022